Piper Sandler initiated coverage of Nektar (NKTR) with an Overweight rating and $7 price target The analyst believes Nektar’s lead asset rezpegaldesleukin has a differentiated IL-2Ralpha mechanaism of action that selectively stimulates tregs. The firm has a high probability of success for rezpegaldesleukin, saying the Phase 1b atopic dermatitis trial demonstrated robust efficacy and safety and validated the utility of targeted treg stimulation.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio